BioAge Labs registers Phase 2 study of oral BGE-102 in diabetic macular edema

BioAge Labs had one item posted for the week, a newly registered Phase 2 trial in an eye disease indication.

• "QUELL-DME" (NCT07812090), a Phase 2 study of oral BGE-102 in participants with center-involved diabetic macular edema, is listed as recruiting with an actual start date of August 21, 2026. The trial plans to enroll 180 participants across three arms comparing BGE-102 monotherapy, BGE-102 combined with anti-VEGF therapy, and anti-VEGF monotherapy¹. The primary outcome is change from baseline in Best Corrected Visual Acuity as measured by the Early Treatment Diabetic Retinopathy Study scale at Week 12¹, with a single U.S. site in McAllen, Texas listed as recruiting¹.